Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on November 12, 2015. The report addresses a specific corporate event regarding the distribution of company stock by a major shareholder, New Enterprise Associates, effective following the close of trading on November 11, 2015.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or operational metrics.
Material Changes
The primary material event reported is the distribution of 3,820,625 shares of Supernus Pharmaceuticals common stock by New Enterprise Associates to its limited partners. This distribution occurred effective after market close on November 11, 2015.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the disclosure of the share distribution event. No unusual items or contingencies were detailed in the text provided.
Investor Verification Checklist
- Verify the impact of the 3,820,625 share distribution on the company's total outstanding share count and potential dilution.
- Review the attached Press Release (Exhibit 99.1) for additional context on New Enterprise Associates' remaining stake.
- Confirm the timing of the distribution relative to the November 11, 2015 market close.